CH ENV TECH & BIO(01237)

Search documents
中科生物(01237) - 2024 - 年度财报
2025-04-29 09:28
Stock Code 股份代號: 1237 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) 2024 年報 ANNUAL REPORT Contents 目錄 | Corporate Information | 公司資料 | 2 | | --- | --- | --- | | Financial Summary | 財務概要 | 5 | | Management Discussion and Analysis | 管理層討論與分析 | 8 | | Corporate Governance Report | 企業管治報告 | 14 | | Directors' Report | 董事會報告 | 32 | | Board of Directors and Senior Management | 董事會及高級管理層 | 49 | | Independent Auditor's Report | 獨立核數師報告 | 52 | | Consolidated Statement of Profit or Loss a ...
宁夏中科生物科技股份有限公司2025年第一季度报告
Shang Hai Zheng Quan Bao· 2025-04-26 09:26
登录新浪财经APP 搜索【信披】查看更多考评等级 □是 √否 一、主要财务数据 主要会计数据和财务指标 单位:元 币种:人民币 ■ 证券代码:600165 证券简称:*ST宁科(维权) 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假 记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的,以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目,应说明原因。 □适用 √不适用 主要会计数据、财务指标发生变动的情况、原因 √适用 □不适用 ■ ...
宁夏中科生物科技股份有限公司关于公司及实际控制人收到《行政处罚决定书》的公告
Shang Hai Zheng Quan Bao· 2025-04-06 18:20
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:600165 股票简称:*ST宁科 公告编号:临2025-048 宁夏中科生物科技股份有限公司 关于公司及实际控制人收到《行政处罚决定书》的公告 公司及虞建明先生于2025年4月3日收到中国证监会宁夏监管局下发的《行政处罚决定书》(宁证监处罚 字[2025]2号),相关情况公告如下: 一、《行政处罚决定书》内容 当事人:宁夏中科生物科技股份有限公司(以下简称*ST宁科或公司),注册地址、办公地址均为宁夏 回族自治区石嘴山市惠农区河滨街。 虞建明,男,1973年2月出生,*ST宁科实际控制人。住址:上海市浦东新区。 黄海粟,女,1985年2月出生,时任*ST宁科董事长、宁夏中科生物新材料有限公司(以下简称中科新 材)董事长,住址:上海市黄浦区。 陈瑞,男,1973年11月出生,时任*ST宁科总经理、中科新材总经理,住址:宁夏石嘴山市惠农区。 董春香,女,1987年3月出生,*ST宁科财务总监,住址:宁夏银川市金凤区。 吴江明,男,1973年10月出生,时任*ST宁科董事长、中科新材董事长,住址:上海市徐汇区。 本公司董事会及全体董事保证本公告内容不存在 ...
上交所对宁夏中科生物科技股份有限公司及实际控制人虞建明和有关责任人予以纪律处分
Mei Ri Jing Ji Xin Wen· 2025-04-03 09:38
每经AI快讯,2025年4月3日,上交所发布关于对宁夏中科生物科技股份有限公司及实际控制人虞建明 和有关责任人予以纪律处分的决定。 董春香,宁夏中科生物科技股份有限公司时任财务总监; 当事人: 宁夏中科生物科技股份有限公司,A股证券简称:*ST宁科,A股证券代码:600165; 虞建明,宁夏中科生物科技股份有限公司实际控制人; 郑杰,宁夏中科生物科技股份有限公司控股股东上海中能企业发展(集团)有限公司时任财务总监; 黄海粟,宁夏中科生物科技股份有限公司时任董事长兼宁夏中科生物新材料有限公司董事长; 胡春海,宁夏中科生物科技股份有限公司时任董事长(代行董事会秘书); 吴江明,宁夏中科生物科技股份有限公司时任董事长兼宁夏中科生物新材料有限公司董事长; 祝灿庭,宁夏中科生物科技股份有限公司时任总经理; 陈瑞,宁夏中科生物科技股份有限公司时任总经理兼宁夏中科生物新材料有限公司总经理; 张宝林,宁夏中科生物科技股份有限公司时任董事会秘书; 范昌盛,宁夏中科生物科技股份有限公司时任财务部部长兼宁夏中科生物新材料有限公司财务总监; 韩昆山,宁夏中科生物新材料有限公司副总经理。 一、上市公司及相关主体违规情况 根据中国证监会 ...
中科生物(01237) - 2024 - 年度业绩
2025-03-31 12:29
Financial Performance - The total revenue for the year ended December 31, 2024, was RMB 409.62 million, representing a 37.6% increase from RMB 297.53 million in 2023[3]. - Gross profit for the same period was RMB 49.72 million, up from RMB 20.18 million, indicating a significant improvement in profitability[3]. - The net profit for the year was RMB 2.98 million, a turnaround from a net loss of RMB 2.36 million in 2023[3]. - For the year ended December 31, 2024, total revenue from external customers reached RMB 409,620,000, an increase from RMB 297,530,000 in 2023, representing a growth of approximately 37.5%[18][19]. - The revenue from the production and sale of wooden products was RMB 407,382,000 for 2024, compared to RMB 295,084,000 in 2023, indicating a growth of about 37.9%[18][19]. - The company reported a net profit of RMB 2,983,000 for the year ended December 31, 2024, recovering from a net loss of RMB 2,364,000 in 2023[18][19]. - Total revenue for the group increased by 37.7% to RMB 409.6 million in 2024, compared to RMB 297.5 million in 2023[46]. - Gross profit increased to approximately RMB 49.7 million in 2024, with a gross margin of 12.1%, up from RMB 20.2 million and a gross margin of 6.8% in 2023[47]. Assets and Liabilities - The company reported a total current asset value of RMB 758.23 million, an increase from RMB 515.11 million in 2023[5]. - Current liabilities rose to RMB 207.48 million from RMB 165.20 million, reflecting increased operational activities[6]. - The total non-current assets decreased to RMB 452.60 million from RMB 539.63 million, primarily due to depreciation[5]. - The total assets increased to RMB 1,210,828,000 in 2024 from RMB 1,054,741,000 in 2023, reflecting a growth of approximately 14.8%[20]. - The total liabilities rose to RMB 335,972,000 in 2024, up from RMB 182,369,000 in 2023, marking an increase of about 84.5%[20]. - Trade receivables increased to RMB 95,303 thousand in 2024 from RMB 62,181 thousand in 2023, reflecting a growth of approximately 53.3%[35]. - Total trade and other receivables rose to RMB 157,009 thousand in 2024, up from RMB 113,143 thousand in 2023, marking an increase of about 38.8%[35]. - Trade payables surged to RMB 85,309 thousand in 2024, compared to RMB 32,505 thousand in 2023, representing a growth of approximately 162.5%[37]. - The company has bank financing agreements totaling RMB 241,400 thousand in 2024, a significant increase from RMB 111,900 thousand in 2023[39]. Expenses and Costs - Interest expenses on bank loans increased to RMB 3,860,000 in 2024 from RMB 1,331,000 in 2023, indicating a rise of approximately 189.5%[24]. - Employee costs, excluding director remuneration, rose to RMB 29,405,000 in 2024 from RMB 19,692,000 in 2023, representing an increase of about 49.5%[25]. - Administrative expenses increased to RMB 37.6 million in 2024, up from RMB 31.8 million in 2023, primarily due to increased R&D expenditures[51]. - The company reported a foreign exchange loss of RMB 21,822,000 in 2024, compared to a gain of RMB 10,296,000 in 2023[23]. Tax and Other Income - The company's income tax expense for 2024 was RMB (7,184) thousand, compared to RMB 466 thousand in 2023, indicating a significant increase in tax credits or reductions[9]. - Other income rose to RMB 30.2 million in 2024, compared to RMB 24.8 million in 2023, primarily from bank interest and government subsidies[48]. - The company received government subsidies of RMB 423,000 in 2024, a significant decrease from RMB 3,966,000 in 2023[22]. Shareholder Information - The basic earnings per share for the year was RMB 0.03, compared to a loss per share of RMB 0.03 in 2023[4]. - The average number of ordinary shares for calculating basic and diluted earnings per share remained constant at 92,137,051 for both 2024 and 2023[32]. - The board of directors did not recommend a final dividend for the year ending December 31, 2024[67]. Corporate Governance and Compliance - The audit committee reviewed the group's annual performance for the reporting year[65]. - The group has maintained compliance with corporate governance codes, with deviations noted in meeting frequency and information updates to the board[62][63]. - The group has not purchased, sold, or redeemed any listed securities during the reporting year[61]. - There were no significant events occurring after the reporting period[59]. - The group has not granted any share options since the adoption of the share option scheme on June 15, 2012[58]. Market Position and Strategy - The global wooden products industry is experiencing transformative growth driven by increasing demand for sustainable building materials and eco-friendly consumer goods[60]. - The group has a strategic advantage in the bioenergy and wooden products sectors, anticipating further revenue enhancement in the coming years[60]. - The group is well-positioned to capitalize on the shift towards a circular economy, aligning with global decarbonization goals[60].
中科生物(01237) - 2024 - 中期财报
2024-09-26 09:44
Revenue Performance - The Group's revenue increased by 4% to RMB186.5 million for the six months ended June 30, 2024, compared to RMB179.4 million in the same period of 2023[7]. - Revenue from the manufacturing and sales of wooden products rose by 4.2% to RMB185.4 million, accounting for 99.4% of total revenue[11]. - Revenue from renewable energy products was RMB1.1 million, representing 0.6% of total revenue, down from RMB1.5 million in 2023[11]. - The Group's revenue from wooden products increased by 4.2% to RMB185.4 million, representing 99.4% of total sales for the Period[14]. - Revenue from the renewable energy business decreased by 31.2% to approximately RMB1.1 million due to reduced demand in the domestic market[15]. - The Group's revenue for the six months ended June 30, 2024, was RMB 186,491,000, an increase from RMB 179,417,000 in the same period of 2023, representing a growth of approximately 6.0%[97]. - Sales of outdoor wooden products amounted to RMB 185,431,000, while sales of renewable energy products were RMB 1,060,000 for the same period[97]. - The revenue from the primary geographical market of Australasia was RMB 135,804,000, contributing significantly to the overall revenue[100]. Profitability and Loss - The gross profit margin decreased to 7.2% in 2024 from 12.1% in 2023, resulting in a gross profit of RMB13.4 million, down from RMB21.7 million[7]. - The Group recorded a loss of approximately RMB1.7 million for the Period, compared to a profit of RMB2.7 million in the previous year[22]. - Loss for the period was RMB 1,715,000, a decline from a profit of RMB 2,733,000 in the same period last year[76]. - The consolidated loss after taxation for the first half of 2024 was RMB 1,715,000, compared to a profit of RMB 2,733,000 in the same period of 2023[108]. - Loss before taxation for the six months ended June 30, 2024, was RMB 8,804,000, compared to RMB 3,052,000 in 2023, indicating a significant increase in losses[120]. Expenses and Costs - Selling and distribution expenses rose by 24.1% to RMB10.8 million, mainly due to increased shipping and other selling expenses[18]. - Administrative expenses decreased to RMB18.0 million, attributed to increased research and development costs and corporate expenses[22]. - Finance costs increased to approximately RMB8.8 million, mainly representing interest payments for bank loans[22]. - The cost of inventories for the six months ended June 30, 2024, was RMB 173,110,000, up from RMB 157,681,000 in 2023, reflecting an increase of 9.8%[121]. - Research and development costs decreased to RMB 960,000 in 2024 from RMB 2,637,000 in 2023, a reduction of 63.6%[121]. Financial Position - As of June 30, 2024, the Group had current assets of RMB475.3 million, with cash and cash equivalents at RMB13.6 million[22]. - Total current liabilities rose to RMB 247,525,000 from RMB 165,199,000, indicating an increase of 49.7%[77]. - Current assets increased to RMB 722,837,000, compared to RMB 515,109,000 at the end of 2023, representing a growth of 40.3%[77]. - Total equity as of June 30, 2024, was RMB 876,674, a slight increase from RMB 872,372 at the end of 2023, reflecting a growth of approximately 0.3%[78]. - The company’s retained profits as of June 30, 2024, were RMB 55,538, compared to RMB 62,752 as of June 30, 2023, indicating a decrease of about 11.5%[80]. Shareholder Information - Mr. Wu Zheyan holds a total of 10,695,407 shares, representing approximately 11.61% of the company's shareholding interest[43]. - Green Seas Capital Limited, wholly owned by Mr. Wu Zheyan, holds 8,992,948 shares, accounting for 9.76% of the total shares[46]. - Hong Kong Cheng Kun Holdings Limited owns 8,472,000 shares, which is 9.19% of the company's total shares[46]. - Hong Kong Guoyuan Group Capital Holdings Limited has a significant holding of 14,035,000 shares, representing 15.23%[46]. - Ms. Han Hong holds 9,965,390 shares, which is approximately 10.82% of the company's shareholding[48]. Corporate Governance and Compliance - The interim financial report is unaudited, with detailed financial statements provided in the report[2]. - The Group has complied with the Corporate Governance Code, except for provisions C.5.1 and D.1.2[61]. - The auditor's report on the financial statements for the year ended December 31, 2023, was unqualified, indicating no significant issues were raised[92]. - The financial statements for the year ended December 31, 2023, have been delivered to the Registrar of Companies as required by law[92]. Market and Economic Environment - The Group's customers remained conservative in purchasing due to global economic instability, impacting overall sales performance[11]. - Global GDP growth is expected to be around 2.8% in 2024 and 2025, with risks tilted to the downside due to geopolitical uncertainties[31]. - The management discussion highlights challenges in the market environment affecting sales strategies and future outlook[7]. Future Outlook and Strategies - The Group's performance in the first half of 2024 shows a positive trend, indicating potential for future growth in both product categories[97]. - Future strategies include exploring new markets and potential acquisitions to drive growth in both segments[102]. - The Group is focusing on expanding its manufacturing capabilities in both wooden and renewable energy products to enhance market presence[102]. Share Option and Award Schemes - The Share Option Scheme allows the Board to grant options to eligible participants, with a maximum of 10% of the total shares issued (100,000,000 shares) post-Global Offering[50]. - The Share Award Scheme permits the issuance of up to 20% of the total issued shares (741,200,400 shares), with a maximum of 2% awarded to any selected individual[54]. - The Group granted 3,900,000 Award Shares to 7 employees, representing approximately 4.23% of the total shares in issue, with a vesting period of 12 months[164]. - The Board resolved not to declare any interim dividend for the Period[61].
中科生物(01237) - 2024 - 中期业绩
2024-08-30 13:29
香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不就因本公佈全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CHINA ENVIRONMENTAL TECHNOLOGY AND BIOENERGY HOLDINGS LIMITED 中科生物控股有限公司 (於開曼群島註冊成立的有限公司) (股份代號:1237) 二零二四年度中期業績公佈 中科生物控股有限公司(「本公司」)董事會(「董事會」)宣佈本公司及其附屬公司 (統稱「本集團」)截至二零二四年六月三十日止六個月的未經審核業績。本公佈列 載本公司二零二四年度中期報告全文,並符合香港聯合交易所有限公司證券上市 規則中有關中期業績初步公佈附載的資料的要求。 股息 董事會不建議就截至二零二四年六月三十日止六個月向股東派付任何中期股息。 於聯交所及本公司網站刊登二零二四年度的中期報告 本公佈亦會刊登於聯交所(www.hkexnews.hk)及本公司(www.merrygardenholdings.com) 網站,而載有上市規則規定所有資料的本公司二零二四年度的中期報告, ...
中科生物(01237) - 2023 - 年度财报
2024-04-29 10:47
Stock Code 股份代號: 1237 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) 2023 年報 ANNUAL REPORT Contents 目錄 | Corporate Information | 公司資料 | 2 | | --- | --- | --- | | Financial Summary | 財務概要 | 5 | | Management Discussion and Analysis | 管理層討論與分析 | 8 | | Corporate Governance Report | 企業管治報告 | 14 | | Directors' Report | 董事會報告 | 32 | | Board of Directors and Senior Management | 董事會及高級管理層 | 49 | | Independent Auditor's Report | 獨立核數師報告 | 52 | | Consolidated Statement of Profit or Loss a ...
中科生物(01237) - 2023 - 年度业绩
2024-03-28 11:55
Financial Performance - The total revenue for the year ended December 31, 2023, was RMB 297.53 million, a decrease of 36% compared to RMB 465.04 million in 2022[4] - The gross profit for the year was RMB 20.18 million, down 62.6% from RMB 53.87 million in the previous year[4] - The net loss for the year was RMB 2.36 million, improving from a net loss of RMB 6.78 million in 2022[4] - Other income increased to RMB 24.78 million from RMB 15.83 million, representing a growth of 56.5%[4] - The total revenue for outdoor wooden products decreased to RMB 295,084 thousand in 2023 from RMB 460,742 thousand in 2022, representing a decline of approximately 36%[18] - Revenue from renewable energy products also fell to RMB 2,446 thousand in 2023 compared to RMB 4,295 thousand in 2022, a decrease of about 43%[18] - The total reportable segment revenue for wooden products was RMB 298,910 thousand in 2023, down from RMB 465,891 thousand in 2022, reflecting a decline of approximately 36%[25] - The reportable segment loss (excluding government subsidies) for wooden products was RMB (6,120) thousand in 2023, compared to a loss of RMB (11,548) thousand in 2022[25] - The company reported a loss attributable to shareholders of RMB 2,364,000 for the year ended December 31, 2023, compared to a loss of RMB 6,558,000 for the previous year, indicating a significant improvement in performance[40] Assets and Liabilities - Total assets as of December 31, 2023, amounted to RMB 1,404.74 million, compared to RMB 1,114.59 million in 2022, indicating a growth of 25.9%[10] - Current liabilities increased to RMB 165.20 million from RMB 129.52 million, a rise of 27.5%[12] - The company’s cash and cash equivalents decreased to RMB 32.50 million from RMB 113.77 million, a decline of 71.5%[10] - Non-current assets totaled RMB 539.63 million, an increase from RMB 453.99 million in 2022, reflecting a growth of 18.8%[10] - Total liabilities increased from RMB 136,214 thousand in 2022 to RMB 182,369 thousand in 2023, an increase of about 34%[29] - Trade receivables decreased to RMB 62,181,000 in 2023 from RMB 64,665,000 in 2022, while total trade and other receivables amounted to RMB 113,143,000, down from RMB 122,955,000[41] - Trade payables increased to RMB 32,505,000 in 2023 from RMB 18,531,000 in 2022, indicating a rise in short-term liabilities[45] Expenses and Income - Selling and distribution expenses were RMB 14.7 million, down from RMB 35.5 million in 2022, due to decreased sales volume[62] - Administrative expenses decreased to RMB 31.8 million from RMB 48.0 million, mainly due to reduced R&D spending[63] - Financing costs rose to approximately RMB 1.4 million from RMB 1.0 million, primarily due to bank loan interest[64] - Interest income from bank deposits rose to RMB 16,194 thousand in 2023 from RMB 7,817 thousand in 2022, an increase of approximately 107%[31] - The company recognized income tax expenses of RMB 466,000 for 2023, compared to a tax credit of RMB 359,000 in 2022, reflecting a shift in tax obligations[35] Shareholder Information - The company reported a basic and diluted loss per share of RMB 0.03 for the year, unchanged from the previous year[9] - The weighted average number of ordinary shares for calculating basic loss per share increased to 92,137,051 in 2023 from 87,234,989 in 2022 due to a share consolidation[36] - A share consolidation was approved, merging every 10 existing shares into 1, effective January 2, 2024[53] - The board did not recommend a final dividend for the year ending December 31, 2023[81] Operational Changes - The company has implemented new and revised international financial reporting standards, which did not have a significant impact on the financial position and performance for the year[14] - The company completed the sale of its subsidiary, Zhangzhou Xingruixiang Supply Chain Management Co., Ltd., on November 3, 2023, with proceeds of approximately RMB 838,000[44] - The company has no forfeited contributions under its retirement benefit plans in China and Hong Kong for the years ended December 31, 2023, and December 31, 2022[34] - The company’s investment properties are recorded at cost less accumulated depreciation and impairment, with no specific figures provided for the year[39] Market Outlook - The IMF warned of a potential global economic slowdown due to high inflation and financial instability, predicting global trade growth of only 3.3% in 2024[73] - The group will continue to adopt a prudent approach and aims to expand its business footprint to stabilize shareholder returns[73]
中科生物(01237) - 2023 - 中期财报
2023-09-20 08:32
Stock Code 股份代號: 1237 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) 2023 中期報告 INTERIM REPORT Contents 目錄 | Corporate Information | 公司資料 | 2 | | --- | --- | --- | | Management Discussion and Analysis | 管理層討論與分析 | 5 | | Other Information | 其他資料 | 14 | | Consolidated Statement of Profit or Loss | 綜合損益表-未經審核 | 24 | | – Unaudited | | | | Consolidated Statement of Profit or Loss and | 綜合損益及其他全面收益表 | 25 | | Other Comprehensive Income – Unaudited | -未經審核 | | | Consolidated Statement o ...